In Japan, the genito-urinary system and sex hormones market sees gradual sales decline from 1.5% of total sales in 2024 to 1.2% in 2028. Year-on-year, there’s a consistent decrease, with noticeable declines starting from 2026. In 2022 and 2023, the segment stood at a higher percentage, highlighting the downward trend. The compound annual growth rate (CAGR) from 2024-2028 underscores a negative trajectory, averaging negative growth per year.

Future trends to monitor include:

Introduction of novel therapies and medications impacting market share.
Regulatory changes potentially altering demand dynamics.
Demographic shifts influencing consumption patterns.
Potential impacts from healthcare policy reforms on drug pricing and availability.